questions as to whether one should initiate long-term treatment with drug combinations, or whether an ineffective medication should be switched or combined (augmented) . Existing studies of combination treatments are either inconclusive, methodologically problematic, or answer another question altogether.
A common reason for using drug combinations is monotherapy failure. No existing medication works for all cases of BD. After concluding that a person is not responding, a decision needs to be made about the future direction of the treatment. This may, but does not have to, be a medication change. Treatment outcome can be influenced by therapeutic alliance, improving compliance and providing patient education, as well as addressing side effects. In some cases, reassessment may show that the patient was initially misdiagnosed and requires a different treatment altogether. Data on effectiveness of combinations are scarce. In several studies (mostly case series and open treatment trials), patients who failed previous treatment with a single drug improved when a second drug was added. But this does not answer the question if the combination is superior to monotherapy with the second drug. The key study-whether patients who failed A respond better to A + B than to B alone-has not been done.
The value of combination treatments has also been tested in several recent trials of atypical antipsychotics based on discontinuation designs. Patients who responded to a combination of drugs (a new drug added to a traditional mood stabilizer) were randomized to continue the combination or just one part of it (the traditional drug). Some, but not all, such studies showed benefits of staying on a combination 4, 5 ; while combination treatments in these studies usually led to higher rates of side effects. However, it is problematic to base practical recommendations on such results for 2 reasons. First, these studies were based on so-called enriched design. Patients who improved on a drug (alone or in combination) can be expected to relapse more likely if that drug is discontinued. Second, the data can at best answer the question of whether to continue a combination if it has been effective. However, in these situations, the clinical decision can hardly be based on random discontinuation. If a patient had insufficient response to A, and B has been added, producing an improvement, then it makes little sense to return to A alone. Most clinicians would want to know whether to continue the combination instead of switching to B. However, none of these studies examined the effects of stopping the first drug and continuing with the new one only.
Only 2 trials have examined combinations of 2 mood stabilizers as an initial long-term treatment. In the study by Denicoff et al, 6 patients were sequentially treated first with lithium or carbamazepine, next with the other of the 2, and finally with the combination, with each treatment for 1 year. The study suffered from high dropout rates, but did not find overall differences between the treatments, although the combination appeared marginally better in patients with rapid cycling. 6 A second study of 12 patients randomized to either lithium or lithium and divalproex showed a better effect of the combination, but its interpretation was hampered by several factors: a very small sample, incomplete recovery of some patients at the time of randomization, and uncontrolled use of additional medication including antidepressants and antipsychotics. 7 Finally, several older studies found no benefit of adding an antidepressant to lithium for long-term treatment, with the combination groups reporting more adverse responses.
The lack of evidence for combination treatments is also acknowledged in most BD guidelines. The most skeptical are the Danish guidelines; other guidelines recommend combinations as second-or third-line treatments in refractory cases.
In the end, there is perhaps one reason why physicians may consider a combination of lithium and another drug in patients who failed a trial of lithium monotherapy. In a single retrospective analysis, Ahrens and Muller-Oerlinghausen 8 suggested that even patients who continue experiencing episodes of illness on lithium show a reduction of suicides and suicide attempts if they remain on lithium. Should these results be confirmed, lithium could be recommended as an add-on treatment for patients with a high risk of suicidal behaviour.
Are There Reasons Not to Use Combinations?
There is little data to recommend combinations on the strength of evidence of their effectiveness. Despite that, one could argue that a combination may be a reasonable option ("it makes sense, intuitively") if there is no harm in using it ("just to be on the safe side"). To answer this question, we need more safety data. Most medications have the potential to produce side effects and treatments for BD are no exception. Combining multiple drugs can lead to unpredictable drug-drug interactions as well. While studies of combinations are limited, they do suggest that side effects may be more frequent in comparison with monotherapies. In addition to side effects, we need to be concerned about certain treatments (and combinations) aggravating the symptoms and the clinical course of BD. Except for the effects of antidepressants, this question has not been well studied at all.
Conclusion
Data are lacking from controlled trials supporting the use of combinations as an initial treatment or in situations where monotherapy failed. It is possible that some patients benefit from combinations; however, determining if this is the case on an individual basis is often difficult. This is not to say that combinations must not be used, but rather to caution that in the absence of controlled data, we should view such treatments as individual trials that need to be carefully monitored and documented. It is hard enough to find support for a combination of 2 drugs, yet, these days, many patients are receiving 3 or more mood stabilizers. 9 With each additional medication, the treatment becomes even more trial and error. Many patients with BD are not treated, and those that are, do not receive optimal treatment. 10 Our field should make it a priority to ensure that such patients receive an optimized treatment. For combinations, we should maintain a skeptically rational approach. If a physician has used all of their skills and the patient has not responded to tested and tried treatments, then it may be a time to use less traditional options including combinations. However, these need to be viewed as an exception rather than a standard of practice.
Martin Alda

Monotherapy Is Not as Good as Polypharmacy for BD
C haracterized by different types of mood episodes and varied course, BD is a complex psychiatric condition. Is monotherapy or sequential monotherapy (monotherapy with different agents for different phases) as effective as rational polytherapy for BD? No. And here is a summary of the evidence that rational polypharmacy is a better choice for the overwhelming number of patients with BD.
Does Any Monotherapy Work for All Phases of BD?
Lithium Lithium has been considered the gold standard for management of BD. However, lithium has proven efficacy mainly for acute mania and for maintenance treatment of BD. As well, it should be recognized that the onset of action for lithium in patients with very acute mania is slower than is desirable, thus necessitating the use of antipsychotics, which have a more rapid onset of antimanic efficacy. Further, the efficacy of lithium in treating acute bipolar depression remains controversial. Indeed, in contrast to older literature, a recent placebo-controlled, double-blind trial demonstrated that lithium was not superior to placebo in treating acute bipolar depression. 1 Further, and more importantly, long-term prospective studies suggest that even in patients that are considered good candidates for lithium therapy, only one-quarter of patients remain episode-free during a 10-year period, indicating that lithium monotherapy is ineffective for most patients with BD. 2
Anticonvulsants
Anticonvulsants are frequently used in the management of BD 3 ; however, none has been shown to be effective for all phases of BD. For instance, lamotrigine is effective for prophylaxis of depression and it likely has some efficacy for acute bipolar depression, but it has little efficacy in treating acute mania or preventing mania.
Valproate has been shown to have efficacy in acute mania but the only large double-blind trial conducted, to date, failed to show its efficacy in prophylaxis of mood episodes. 4 Interestingly, in this study, lithium also failed to separate from placebo, raising questions about the assay sensitivity of this study. Among the 3 small placebo controlled trials of efficacy of valproate for acute bipolar depression, 2 showed efficacy while 1 did not. 5 Carbamazepine has efficacy for acute mania but no large placebo-controlled, double-blind trials assessed the efficacy for acute bipolar depression or for prevention of mood episodes. Hence, overall, there is no convincing evidence that anticonvulsant monotherapy is effective for all phases of BD.
Atypical Antipsychotics
This brief review will focus on atypical antipsychotics, as conventional antipsychotics have largely only proven efficacy in acute mania. Among the atypical antipsychotics, quetiapine has proven efficacy in placebo-controlled, double-blind trials for mania, depression, and relapse prevention of BD. 6 While this makes quetiapine monotherapy a potential treatment for all phases of BD, there is evidence that quetiapine, when combined with lithium or valproate, is more effective for acute mania 7 and prevention of both depressive and manic episodes than monotherapy with lithium or valproate (further elaborated in the next section). 8 However, the efficacy of this combination has not been assessed for acute bipolar depression.
Olanzapine is also effective for acute mania and for prevention of mood episodes. Although olanzapine separated from placebo for acute bipolar depression and for prevention of depressive episodes, the effect size and the magnitude of benefit for depression was limited, and likely clinically not meaningful when olazapine is given in monotherapy. 6 Further, olanzapine when combined with fluoxetine is more effective for acute bipolar depression than olanzapine monotherapy, and in combination with lithium or valproate is more effective for mania than monotherapy with lithium or valproate. 9 Risperidone is effective for acute mania 9 and prevention of manic episodes, 10 while its efficacy in acute bipolar depression remains unknown.
Aripiprazole is effective for acute mania and prevention of manic episodes, 11 while it appears ineffective for acute bipolar depression 12 and in the prevention of depressive episodes in monotherapy.
Ziprasidone is effective for mania 6 ; however, its efficacy in other phases has not been assessed.
Therefore, in summary, lithium, lamotrigine, quetiapine, olanzapine, and aripiprazole are the only medications that have been tested in large placebo-controlled, double-blind trials for all phases of BD. Among these, only quetiapine and olanzapine have positive data for monotherapy for all phases. However, there is evidence that monotherapy with either of these agents is not as good as combining quetiapine or olanzapine with other medications such as lithium or valproate or fluoxetine for the different phases of BD.
Is monotherapy as good as polytherapy when given sequentially for each phase of BD? This question can be addressed by examining studies that compared monotherapy with combination therapy for each phase of BD separately.
Acute Mania
During the past decade, several randomized placebocontrolled trials assessed the efficacy of 2 or more agents in comparison with monotherapy plus placebo for acute mania. 9 These studies have shown that combination therapy of risperidone or olanzapine or quetiapine with lithium or valproate is more effective than monotherapy with lithium or valproate. Similarly, a combination of valproate and a conventional antipsychotic combination is more effective than a conventional antipsychotic monotherapy. Overall, about 20% more patients respond to combination therapy relative to monotherapy. This translates to a number needed to treat of 5, which means that of every 5 patients treated with combination therapy, 1 more patient will improve with this strategy, compared with monotherapy. Further, one must not underestimate the effectiveness of combination treatment on onset of efficacy, achievement of symptom remission, and shorter hospital stays in the management of acute mania. This has a significant impact not only on patient well-being but also on health economic benefits. Therefore, combination therapy is clearly superior to monotherapy for acute mania. The only exception to this rule is that combining carbamazepine to an atypical antipsychotic does not appear to provide any additional benefit. This is likely due to the effect of carbamazepine on serum levels of atypical antipsychotics such as risperidone and olanzapine, as carbamazepine induces hepatic microsomal enzymes and thus reduces serum levels of atypical antipsychotics.
Acute Bipolar Depression
Relative to mania, few studies systematically examined the efficacy of monotherapy in comparison with combination therapy for acute bipolar depression. 13 Among studies that assessed the relative efficacy of combination over monotherapy, most reported greater efficacy for combination over monotherapy. For instance, lithium in combination with paroxetine is more effective than lithium alone in patients with serum levels below 0.8 mmol/L but not in those that had higher serum levels. However, it must be remembered that many subjects have difficulty tolerating lithium at higher levels. Further, the window between therapeutic levels above 0.8 mmol/L and toxic levels is very narrow, as patients can experience toxicity symptoms at 1.2 mmol/L or more. Addition of lamotrigine to lithium led to greater improvement in depressive symptoms, compared with the addition of placebo, in patients with BD I and II depression. 14 In patients with acute BD depression, a combination of olanzapine plus fluoxetine is more effective than olanzapine monotherapy.
Maintenance Treatment of BD
Most studies that assessed combination therapy, compared with monotherapy, reported superiority of combination in preventing and (or) delaying mood episodes. Lithium and valproate or lithium and carbamazepine combination is superior to monotherapy in preventing relapses in BD. Fewer patients who achieved both syndromic and symptomatic remission with olanzapine plus lithium or valproate relapsed during the next 18 months when olanzapine was continued with lithium or valproate, compared with substituting olanzapine with placebo. 6 There is also evidence that continuing quetiapine in combination with lithium or valproate not only reduces a risk of manic relapse but also depressive relapse in patients with BD I, compared with monotherapy with lithium or valproate. 8 Further, a recent study showed that long-acting injectable risperidone provided additional mood stability by reducing risk of relapse in frequently relapsing patients with BD, compared with placebo injection plus treatment as usual. 15 Overall, these data suggest that combination therapy or rational polypharmacy is more effective than monotherapy in the prevention of mood episodes in BD.
Summary and Conclusions
BD is a severe lifetime condition with recurrences and relapses. The data from controlled clinical trials and real-world practice suggests that rational polypharmacy is necessary and justifiable for the vast majority of patients at different periods in their management. Monotherapy has limited effectiveness and is less clinically relevant for the majority of patients with BD, except for brief periods. Only a small minority of patients can be maintained effectively and successfully on lithium monotherapy. Most commonly these patients will require addition of other psychotrophic medications, depending on the type or course of the mood problems. Although quetiapine and olanzapine are the only 2 medications that have proven efficacy in monotherapy for all phases of BD, they are clearly more effective when they are combined with other medications, compared with monotherapy with lithium or valproate or olanzapine. Combination therapy has been shown to have greater efficacy clearly for acute mania and for maintenance treatment of BD and likely for acute bipolar depression. However, the benefits of greater efficacy must be weighed against increased liability of side effects with 2 medications, as combining 2 medications with similar side effect profile may increase overall liability of particular side effect such as weight gain and other metabolic sequelae. Therefore, clinicians should be prudent in choosing combinations that offer the most benefit with minimal increase in side effect liability. Clinicians should also constantly reassess the need for continuing certain combinations, and should mix and match treatments as per the patient's needs.
Lakshmi N Yatham
Rebuttals
The More Is Not the Better T he main point emerging from this debate is the absence of useful data. There is no evidence to justify the current practice of combining 3 or more drugs. For combinations of 2 medications, Dr Yatham argues that they are superior to monotherapy, but, in fact, the few available studies were based on enriched designs and thus do not provide a real test. This needs to be viewed against the background of several long-term studies showing that at least 30% of patients can be maintained on lithium monotherapy 1-4 and a proportion of nonresponders to lithium can be treated successfully with other monotherapies. 2 The reader may then wonder what drives the current popular practice of polypharmacy (of which the author of this text is also sometimes guilty). In the following, I will speculate about possible reasons. · Using combinations is seemingly convenient. A thorough assessment is needed to select optimal treatment; this is a time-consuming process requiring many clinical details and collateral history. The same applies to longitudinal monitoring and evaluating the quality of response.
· It is probably easier to add another medication than to stop one. The pressure to limit the length of hospitalization may also contribute to a more aggressive treatment. As a result, most patients discharged from inpatients units or those referred to a specialist are usually treated with multiple medications. Especially in patients who have shown partial response to a combination, the psychiatrist may not be sure which drug could be discontinued without risking deterioration.
· Some authors point to other areas of medicine where combinations of drugs with different modes of action are combined to augment the individual effects. However, we do not know which of the multiple pharmacological effects of mood stabilizers are relevant for their mode of action; and thus it is hard to argue for rational polypharmacy. As well, in certain areas of medicine there is a gradual shift away from combinations (for example, respirology).
· Many published treatment trials are add-on studies, creating a false impression that they tested the advantages of combinations.
· Psychiatry residents, by nature of their training, are more likely exposed to severe, more treatment-resistant and atypical forms of BD and less likely to see patients successfully treated with a single drug (and who visit their physicians infrequently).
· Physicians may get a sense of security with more medications-or simply think, the more the better. In a popular Czech children's book, the writer Josef Capek 5 tells a story of how Doggie and Pussycat bake a cake. To make it the best cake ever, they decide to put in only the best (and their favourite) ingredients-chocolate, sausages, cheese, mice, and whipped cream. Fortunately for them, when they let the cake cool off outside, a bad dog walks by, finds the cake, and eats it-and falls very sick as a result.
The absence of relevant information, in particular data outside of registration trials, raises a question of what needs to be done. To decide whether patients should be treated with polypharmacy or monotherapy, we will need entirely different research designs: studies of monotherapy, compared with combination therapy, in subjects who received neither treatment previously; or studies of monotherapy selected according to predictors of response, compared with algorithmic combination. In either design, large samples will be necessary to compare 2 active treatments. This and the rising cost of clinical trials will restrict how many such studies will be done. Note that 2 recent large studies Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) and Sequenced Treatment Alternatives to Relieve Depression (STAR*D) examined treatments for BD and depression, but neither generated the type of information to answer our question. Until such results are available, monotherapy remains the preferred treatment for BD.
Is Monotherapy as Good as Polypharmacy for BD?
I t would appear that polypharmacy is a term with various meanings, ranging from the strictly rational combinations, with a degree of evidence of effectiveness, to the kitchen-sink polypharmacy that simply piles medications onto to one another in patients who are nonresponsive or functionally impaired. To date, studies assessed the evidence for efficacy for a combination of 2 medications, compared with monotherapy, and the evidence at this point in time suggests that combination of 2 medications is more effective for BD than monotherapy. Whether more than 2 medications are more effective for refractory patients has not been tested systematically in clinical trials. Therefore, I would support only rational polypharmacy, which in clinical practice, should be based on sound logic and available data but also with a plan of periodically assessing and discontinuing those medications that are not effective.
Indeed, Dr Alda agrees that combination therapy is superior to monotherapy for treatment of acute mania. He suggests that the situation with bipolar depression is complex and that combination therapy has not been demonstrated to be superior to monotherapy. While I agree with the former statement, the latter is not entirely accurate, as some, although not all, studies have shown that combination therapy is superior to monotherapy. For instance, lamotrigine as an add-on to lithium was superior to placebo as an add-on to lithium. 1 Similarly, an olanzapine plus fluoxetine combination was more effective than olanzapine plus placebo in treating acute bipolar depression, 2 while paroxetine plus lithium was more effective than lithium plus placebo in patients with serum lithium levels below 0.8 mmol/L. 3 As to the maintenance treatment, only a small minority of patients can be managed on a longer-term basis with monotherapy, and the majority need combination therapy, either for prophylaxis or for management of acute episodes owing to failure of monotherapy prophylaxis. Further, as stated in my original argument, lithium, olanzapine, and quetiapine are the only 3 medications that have been shown to be effective for all phases of BD in monotherapy, and each of these has been shown to be more effective when combined with another medication for maintenance treatment of BD. Dr Alda argues that the studies that demonstrated the efficacy of combination treatment were based on enriched design and that this data can, at best, answer the question of whether to continue a combination if it was effective. I agree and, in fact, would suggest that these studies answer a very common clinical question because in clinical practice, many patients are treated with a combination of lithium or valproate plus an atypical antipsychotic, and it is imperative for clinicians and patients to understand if the continuation of both medications reduce risk of relapse, compared with discontinuing one of those medications. The results of recent trials suggest that the risk of relapse is clearly reduced when quetiapine is continued in patients who had shown acute response to a combination of quetiapine and lithium or valproate. 4 Similar results were obtained for a subgroup of patients who had achieved syndromal remission with olanzapine, as olanzpine continuation reduced risk of relapse. 5 It is important to remember that patients entered into quetiapine or olanzapine studies were not nonresponders to lithium or valproate, as Dr Alda alludes to, and hence one cannot argue that the increased relapse rate in patients on lithium or valproate monotherapy was simply because those patients were nonresponders to mood stabilizer treatment. In a recent trial that assessed the efficacy of long-acting injectable risperidone, frequently relapsing patients who stabilized with long-acting injectable risperidone add-on, were randomized to continuation of the same or switch to placebo. The results indicated that fewer patients in the group that continued risperidone long-acting injectable relapsed, compared with those who switched to placebo. 6 While one could argue that these patients could have done just as well with long-acting injectable risperidone without other psychotropic medications, the fact that these patients had frequent relapses with many other treatments suggests that combination therapy was likely responsible for lower relapse rates.
Having reviewed the evidence and suggested that combination therapy is more effective than monotherapy, both Dr Alda and I agree, as indicated in my original statement, that the risks of side effects of combination treatment must be weighed against the benefits in determining the most appropriate treatment for a given patient. As well, one must not forget the role of psychosocial treatments, as such treatments, as adjuncts to pharmacotherapy, have been shown to reduce relapse rates in patients with BD.
